Anticonvulsant properties of cannabidiol
Turkanis, S.A.; Cely, W.; Olsen, D.M.; Karler, R.
Research Communications in Chemical Pathology and Pharmacology 8(2): 231-246
1974
ISSN/ISBN: 0034-5164 PMID: 4850602 Document Number: 82003
Document emailed within 1 workday
Related Documents
Palmer, G.C.; Murray, R.J.; Cramer, C.L.; Stagnitto, M.L.; Knowles, M.K.; Freedman, L.R.; Eismann, M.S.; Mahmood, N.; Balestra, M.; Borrelli, A.R.; Hudzik, T.J.; McCarthy, D.J. 1999: S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties Journal of Pharmacology and Experimental Therapeutics 288(1): 121-132Hajnsek, F.; Hajnsek, S. 1985: Anticonvulsant properties of clobazam in a group of resistant epileptic patients Lijecnicki Vjesnik 107(3-4): 127-131
Lange, J.; Rump, S.; Ilczuk, I.; Lapszewicz, J.; Rabsztyn, T.; Walczyna, K. 1977: Synthesis and properties of cyclic derivatives of succinic acid with anticonvulsant activity Die Pharmazie 32(10): 579-581
Kamiński, K.; Obniska, J. 2008: Synthesis and anticonvulsant properties of new 1-(2-pyridinyl)- 3-substituted pyrrolidine-2,5-dione derivatives Acta Poloniae Pharmaceutica 65(4): 457-465
Obniska, J.; Zejc, A. 2003: Synthesis, physicochemical and anticonvulsant properties of some n-substituted amides of 3-spirocycloalkylpyrrolidine-2,5-dione Acta Poloniae Pharmaceutica 60(5): 383-390
Shapovalova, V.O.; Shapovalov, V.V. 1998: Spasmophilia in children and the anticonvulsant properties of a new Ukrainian preparation containing a pyrimidine derivative Fiziolohichnyi Zhurnal 44(5-6): 102-105
Jastrzebska-Wiesek, M.; Czarnecki, R.; Marona, H. 2008: The anticonvulsant, local anesthetic and hemodynamic properties of some chiral aminobutanol derivatives of xanthone Acta Poloniae Pharmaceutica 65(5): 591-600
Christiansen, C.; Rødbro, P. 1979: Anticonvulsant-induced osteomalacia. Vitamin D metabolism disorders in epileptics on anticonvulsant therapy Ugeskrift for Laeger 141(5): 280-284
Graziani, G.; Tirone, F.; Barbadoro, E.; Testa, R. 1983: Denzimol, a new anticonvulsant drug. I. General anticonvulsant profile Arzneimittel-Forschung 33(8): 1155-1160
Frey, O.R. 2001: Anticonvulsant weaning? how should anticonvulsant therapy be discontinued? Medizinische Monatsschrift für Pharmazeuten 24(8): 266
Engelbrecht, A. 2014: The Medical Cannabidiol Act: what practitioners need to know Iowa Medicine: Journal of the Iowa Medical Society 104(4): 8; 21
Zuardi, A.W.; Morais, S.L.; Guimarães, F.S.; Mechoulam, R. 1995: Antipsychotic effect of cannabidiol Journal of Clinical Psychiatry 56(10): 485-486
Corroon, J.; Felice, J.F. 2019: The Endocannabinoid System and its Modulation by Cannabidiol (CBD) Alternative Therapies in Health and Medicine 25(S2): 6-14
Borgen, L.A.; Davis, W.M. 1974: Cannabidiol interaction with delta9-tetrahydrocannabinol Research Communications in Chemical Pathology and Pharmacology 7(4): 663-670
Mincis, M.; Pfeferman, A.; Guimarães, R.X.; Ramos, O.L.; Zukerman, E.; Karniol, I.G.; Carlini, E.A. 1973: Chronic administration of cannabidiol in man. Pilot study Amb: Revista da Associacao Medica Brasileira 19(5): 185-190
Malor, R.; Jackson, D.M.; Chesher, G.B. 1975: The effect of delta9-tetrahydrocannabinol, cannabidiol and cannabinol on ether anaesthesia in mice Journal of Pharmacy and Pharmacology 27(8): 610-612
Zuardi, A.W.; Guimarães, F.S.; Moreira, A.C. 1993: Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers Brazilian Journal of Medical and Biological Research 26(2): 213-217
Hine, B.; Torrelio, M.; Gershon, S. 1975: Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats Research Communications in Chemical Pathology and Pharmacology 12(1): 185-188
Lindamood, C.; Colasanti, B.K. 1980: Effects of delta 9-tetrahydrocannabinol and cannabidiol on sodium-dependent high affinity choline uptake in the rat hippocampus Journal of Pharmacology and Experimental Therapeutics 213(2): 216-221
Post, R.M. 1990: ECT: the anticonvulsant connection Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 3(2): 89-92; Discussion: 97-99